Burkholderia cepacia: Difference between revisions
(Text replacement - "* " to "*") |
Elcatracho (talk | contribs) |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Infection occurs in patients who are immune suppressed or those with chronic lung disease (e.g. cystic fibrosis) | *Infection occurs in patients who are immune suppressed or those with chronic lung disease (e.g. [[cystic fibrosis]]) | ||
*Often resistant to multiple antibiotics | *Often resistant to multiple antibiotics | ||
Revision as of 18:48, 24 March 2021
Background
- Infection occurs in patients who are immune suppressed or those with chronic lung disease (e.g. cystic fibrosis)
- Often resistant to multiple antibiotics
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014